←
Samuels - Lab71 posts
Samuels - Lab avatar

Samuels - Lab

@Samuels_lab

We aim to shed new light on the complex networks formed in #melanoma, and learn how we can utilize this information to treat melanoma patients @WeizmannScience

◷ Joined June 2023▧ 24 Photos and videos
AACR avatar
⟳ Samuels - Lab retweeted
AACR@AACR·24 Mar 2025

The Various Layers of Intratumor Heterogeneity and Their Impact on Tumor Immunity: Yardena Samuels will address this topic in a plenary session on Targeting the Cancer Ecosystem (Tuesday, April 29) at #AACR25. Learn more: brnw.ch/21wRxxa @samuels_yardena

Post attachment
Samuels - Lab avatar
Samuels - Lab@Samuels_lab·9 Mar 2025

7/8 Our findings suggest that MIF expression is an important determinant of aggressive tumor growth in low-ITH tumors in melanoma and could lead to new strategies for treating patients with homogeneous, high-MIF-expressing tumors that don't respond to immune checkpoint therapy.

Samuels - Lab avatar
Samuels - Lab@Samuels_lab·9 Mar 2025

6/8 These findings were confirmed using #TCGA melanoma patient data. Overall survival was significantly higher in tumors with low MIF expression.

Post attachment
Samuels - Lab avatar
Samuels - Lab@Samuels_lab·9 Mar 2025

5/8 #CRISPR knockout screens and Single-cell RNA sequencing showed significantly and consistently higher MIF expression in non-rejected vs. rejected tumors. MIF knockout resulted in smaller tumors, reduced TAM infiltration, higher T cells and less exhaustion phenotype.

Post attachment
Samuels - Lab avatar
Samuels - Lab@Samuels_lab·9 Mar 2025

4/8 Thus identifying specific factors in the tumors that explain the variance in survival time of patients with low-ITH tumors. Single-cell RNA sequencing revealed that non-rejected tumors had more pro-tumorigenic M2 macrophages and exhausted T cells compared to rejected tumors.

Post attachment
Samuels - Lab avatar
Samuels - Lab@Samuels_lab·9 Mar 2025

3/8 Using this model, we compared the transcriptomic state of tumor and immune cells in rejected vs. non-rejected tumors upon transplantation and throughout tumor evolution.

Samuels - Lab avatar
Samuels - Lab@Samuels_lab·9 Mar 2025

2/8 To investigate the mechanism(s) responsible for aggressive tumor behavior in low ITH patients we established a novel mouse experimental system that enabled us to tease apart which TME factors play a role in aggressive tumor growth in low-ITH settings.

Samuels - Lab avatar
Samuels - Lab@Samuels_lab·9 Mar 2025

1/8 Low intra-tumor heterogeneity (#ITH) is associated with better patient survival, but a significant amount of low-ITH patients exhibited a poor outcome. Our study aimed to identify factors contributing to immune escape in these tumors.